A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy
Section snippets
Background
The enormous increase in the number of patients receiving antiretroviral therapy (ART) worldwide is a remarkable success story but also poses a considerable burden on resource-limited countries due to the cost of drugs, medical care and laboratory monitoring [1].
As part of its public health approach, the World Health Organisation (WHO) recommends non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART regimens for adult patients and for those failing first-line ART a boosted
Objectives
This study aimed to validate and adapt this approach for a Southern African setting, where HIV-1 subtype C is most prevalent, with the specific aim of determining the sensitivity and negative predictive value the qualitative PCR targeting partial reverse transcriptase for detection of virologic failure when 5 patient specimens are pooled, and to determine the prevalence of mutations detected by sequencing the PCR product of individual specimens from positive pools.
Study population
Samples received at the Diagnostic Virology Laboratory of the National Health Laboratory Service (NHLS) Tygerberg in Cape Town, South Africa, between May 2013 and June 2013 for routine HIV viral load testing were sequentially selected if they met the following inclusion criteria: adult patient; on first-line ART; no HIV viral load testing in the previous 4 months; sufficient specimen volume left after routine testing.
Specimens
Routine viral load testing, using the Abbott RealTime HIV-1 assay with a limit
Results
Table 2 shows the ART data for the study population. The majority of patients were on the current first-line ART regimen in South Africa, consisting of tenofovir, lamivudine and efavirenz.
Twenty-two of the 60 pools were positive. Individual testing revealed 29 (9.7%) samples with a detectable viral load. Of these, 26 samples (8.7%) had viral loads of above 1000 viral RNA copies/ml and were therefore defined as failing ART. Pooled testing detected 24 of those 26 patients. The two samples that
Discussion
The pooled testing algorithm presented here was able to detect 24 of 26 adult patients failing first-line ART according to WHO and South African national criteria and provided drug resistance information on the failing patients.
Pooled viral load testing has been shown to decrease the cost of virological monitoring in adults on first-line ART who have a low prevalence of failure [14], [23]. Qualitative rather than quantitative detection of failure has previously been shown to reduce the cost of
Funding
We were assisted with financial support from the National Health Laboratory Service Research Trust, the Polio Research Foundation and the International Research Training Group (IRTG) 1522 “HIV/AIDS and associated infectious diseases in Southern Africa”.
Competing interests
We hereby declare that there is no conflict of interest.
Ethical approval
The study protocol was approved by the health research ethics committee of Stellenbosch University (reference S12/03/064).
Acknowledgements
We would like to express our gratitude to the NHLS staff that assisted in the study. GvZ initiated the study, HN and LB performed the experiments and analysed the results, under guidance and supervision by GvZ, WP and GS. HN, WP, GvZ, GS, LB wrote and revised the manuscript.
References (32)
- et al.
Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol
J Virol Methods
(2013) UNAIDS report on the global AIDS epidemic 2013, Geneva
(2013)Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
(2013)March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
(2014)The South African antiretroviral treatment guidelines
(2013)- et al.
Running with scissors: using antiretroviral therapy without monitoring viral load
Clin Infect Dis
(2008) - et al.
Getting HIV treatment to the most people
Science
(2012) - et al.
Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots
J Clin Microbiol
(2013) - et al.
Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis
PLoS ONE
(2014) - et al.
Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings
J Antimicrob Chemother
(2009)
Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania
Clin Infect Dis
The use of pooled viral load testing to identify antiretroviral treatment failure
AIDS
Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection
J Acquir Immune Defic Syndr
Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico
J Acquir Immune Defic Syndr
Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource – limited setting
Clin Infect Dis
Pooled HIV-1 viral load testing using dried blood spots to reduce the cost of monitoring antiretroviral treatment in a resource-limited setting
J Acquir Immune Defic Syndr
Cited by (8)
Pooled nucleic acid testing strategy for monitoring HIV-1 treatment in resource limited settings
2019, Journal of Clinical VirologyCitation Excerpt :Pooling based algorithm can also be designed for a minipool comprising 10 pools per sample, which would be very cost-effective; however, the sensitivity of the pooling PCR in identifying one VF (with a VL close to 1000 copies/mL) in a pool of 10 samples will be very difficult. The combined NAT + DR testing were earlier done in United States [32] and South Africa [33]. In the former, the NAT + DR assay was compared with the Roche ultra-sensitive Amplicor HIV-1 monitor viral load assay, and they reported the sensitivity of 100% and specificity of <80% and 71% cost saving.
Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa
2016, The Lancet Infectious DiseasesCitation Excerpt :To reduce test costs, many research laboratories have developed in-house assays with comparable performance.40–43 Costs can be reduced by use of open-source reagents (which limits patent-related costs), reducing number of primers, single-step amplification,40–43 collective bargaining with suppliers (SATuRN/Life Technologies assay, ThermoFisher Scientific, Waltham, MA, USA41,44), partnering with nonprofit manufacturers (Centers for Disease Control and Prevention [CDC]/American Type Culture Collection [ATCC], Manassas, VI, USA/ThermoFisher assay, ThermoFisher Scientific43,45), sequencing only reverse-transcriptase for first-line failures (ART-A assay40), and sample pooling.46 Some assays also have broad HIV-1 subtype coverage and can be used with dried blood spots with reasonable (1000–5000 HIV-RNA copies per mL) amplification sensitivity.47,48
Pooling Sputum Samples for Efficient Mass Tuberculosis Screening in Prisons
2022, Clinical Infectious DiseasesHIV-1 viral load testing in resource-limited settings: Challenges and solutions for specimen integrity
2021, Reviews in Medical VirologyHIV-1 genotypic drug resistance testing and next-generation sequencing
2021, Frontiers in Clinical Drug Research - HIVPooled testing: A tool to increase efficiency of infant HIV diagnosis and virological monitoring
2020, African Journal of Laboratory Medicine